Aeterna Zentaris’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Aeterna Zentaris is a biopharmaceutical company that develops and commercializes drugs for the treatment of orphan endocrine diseases. Read more

Klaus Paulini's photo - President & CEO of Aeterna Zentaris

President & CEO

Klaus Paulini

CEO Approval Rating

90/100

Founded:

1990

Status:

PublicTMX Group - Toronto Stock ExchangeAEZS

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Radius Health is the top competitor of Aeterna Zentaris. Radius Health is a Public company that was founded in Waltham, Massachusetts in 2003. Like Aeterna Zentaris, Radius Health also operates in the Pharmaceuticals sector. Radius Health has 372 more employees vs. Aeterna Zentaris.

MBX Biosciences is seen as one of Aeterna Zentaris's biggest rivals. MBX Biosciences was founded in Carmel, Indiana} in 2018. Like Aeterna Zentaris, MBX Biosciences also competes in the Pharmaceuticals space. Compared to Aeterna Zentaris, MBX Biosciences generates $ less revenue.

Crinetics is perceived as one of Aeterna Zentaris's biggest rivals. Crinetics was founded in 2008, and is headquartered in San Diego, California. Like Aeterna Zentaris, Crinetics also operates in the Biotechnology space. Crinetics generates $32K more revenue vs. Aeterna Zentaris.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Xenetic Biosciences a competitor of Aeterna Zentaris?

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$1.5M

Aeterna Zentaris's revenue is the ranked 19th among it's top 10 competitors. The top 10 competitors average 166.6M. Over the last four quarters, Aeterna Zentaris's revenue has decreased by 76%. Specifically, in Q2 2020's revenue was $ < 1M; in Q1 2020, it was $1.1M; in Q4 2019, it was $ < 1M; in Q3 2019, Aeterna Zentaris's revenue was $ < 1M.

Acquisitions

No recent acquisitions found related to Aeterna Zentaris

Aeterna Zentaris Funding History

$632.7M$637.7M$649.2M

Since Aeterna Zentaris was founded in 1990, it has participated in 4 rounds of funding. In total Aeterna Zentaris has raised $649.2M. Aeterna Zentaris' last funding round was on Aug 2020 for a total of $7.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Private Placement
Aug 2020
$7M
-
Unattributed
Feb 2020
$4.5M
-
Equity
Sep 2019
$5M
-
Series B
Nov 2015
$632.7M
-

Total Funding: $649.2M

Since Aeterna Zentaris was founded in 1990, it has participated in 4 rounds of funding. In total Aeterna Zentaris has raised $649.2M. Aeterna Zentaris' last funding round was on Aug 2020 for a total of $7.0M

Investments

No recent investments found related to Aeterna Zentaris

Aeterna Zentaris News

September 8, 2020Markets Insider

Aeterna Zentaris Announced Presentation of Positive Results from First Pediatric Study of Macimorelin at the 22nd European Congress of Endocrinology | Markets Insider

- PK and PD profiles of macimorelin for pediatric use were within the expected range and comparable t... See more »
August 6, 2020NewsOk

2Q Earnings Snapshot

SUMMERVILLE, S.C. (AP) _ Aeterna Zentaris Inc. (AEZS) on Thursday reported a second-quarter loss of $... See more »
August 6, 2020BioSpace

Aeterna Zentaris Reports Second Quarter 2020 Financial Results and Provides Business Update

- Positive results from AEZS-130-P01 ("Study P01") confirmed dosing regimen of macimorelin as a poten... See more »
August 5, 2020MarketScreener

Aeterna Zentaris Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market

(marketscreener.com) CHARLESTON, S.C., Aug. 05, 2020 -- Aeterna Zentaris Inc. , a specialty biopharma... See more »
July 31, 2020MarketScreener

Aeterna Zentaris Announces Continued Expansion of Intellectual Property Portfolio for Macimorelin with Additional Patent Applications

(marketscreener.com) CHARLESTON, S.C., July 31, 2020 -- Aeterna Zentaris Inc. , a specialty biopharma... See more »
July 30, 2020MarketScreener

AETERNA ZENTARIS ANNOUNCES ABSTRACT OF RESULTS FROM FIRST PEDIATRIC STUDY OF MACIMORELIN ACCEPTED FOR PRESENTATION AT THE 22ND EUROPEAN CONGRESS OF ENDOCRINOLOGY

(marketscreener.com) CHARLESTON, S.C., July 30, 2020 -- Aeterna Zentaris Inc. , a specialty biopharma... See more »

Aeterna Zentaris Press Releases

May 15, 2020centralcharts

Aeterna Zentaris Announces Results of 2020 Annual Meeting of Shareholders

CHARLESTON, S.C., May 15, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (... See more »
April 15, 2020GlobalNewswire

Aeterna Zentaris Receives Nasdaq Notice of Non-Compliance; No Immediate Impact on Listing

CHARLESTON, S.C., April 15, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)... See more »
April 6, 2020GlobeNewswire

AETERNA ZENTARIS ANNOUNCES POSITIVE RESULTS IN DOSE-FINDING PEDIATRIC STUDY OF MACIMORELIN

- Positive results provide clinical framework to advance the Company's Pediatric Investigation Plan f... See more »
March 12, 2020centralcharts

AETERNA ZENTARIS ANNOUNCES SETTLEMENT OF PREVIOUSLY DISCLOSED CLASS-ACTION LAWSUIT

CHARLESTON, S.C., March 12, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)... See more »
February 15, 2020Network Newswire

AEZS) Starts Presentation at NobleCon16 - NetworkNewsWire

Aeterna Zentaris (NASDAQ: AEZS) (TSX: AEZS) is a specialty biopharmaceutical company engaged in comme... See more »
February 12, 2020StreetInsider

Aeterna Zentaris to Present at Noble Capital Markets' 16th Annual Investor Conference

Presentation on Monday, February 17th at 11:30 a.m. ETCHARLESTON, S.C., Feb. 12, 2020 (GLOBE NEWSWIRE... See more »
January 28, 2020GlobeNewswire

Aeterna Zentaris Announces Completion of Patient Recruitment in Dose-Finding Pediatric Study of Macimorelin

- Study P01 is the first of two studies as agreed with the EMA in the Company's Pediatric Investigati... See more »

Headquarters

1155 Rene-Levesque Boulevard West Suite 4100

Montreal, QuebecH3B 3V2

1-843-900-3201

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Aeterna Zentaris is a biopharmaceutical company that develops and commercializes drugs for the treatment of orphan endocrine diseases. Aeterna Zentaris was founded in 1990. Aeterna Zentaris' headquarters is located in Montreal, Quebec, CA H3B 3V2. It ...

CEO

Aeterna Zentaris's President & CEO, Klaus Paulini, currently has an approval rating of 90%. Aeterna Zentaris's primary competitors are Radius Health, MBX Biosciences & Crinetics.

Website

zentaris.com

Frequently Asked Questions about Aeterna Zentaris

  1. When was Aeterna Zentaris founded?

    Aeterna Zentaris was founded in 1990
  2. Who is Aeterna Zentaris's CEO?

    Aeterna Zentaris's CEO is Klaus Paulini
  3. How much revenue does Aeterna Zentaris generate?

    Aeterna Zentaris generates $1.5M in revenue
  4. How much funding does Aeterna Zentaris have?

    Aeterna Zentaris has historically raised $649.2M in funding
  1. Where is Aeterna Zentaris's headquarters?

    Aeterna Zentaris's headquarters is in Montreal Quebec, CA
  2. How many employees does Aeterna Zentaris have?

    Aeterna Zentaris has 11 employees
  3. What sector does Aeterna Zentaris operate in?

    Aeterna Zentaris is in Biotechnology, Pharmaceuticals
  4. Who are Aeterna Zentaris's competitors?

    Aeterna Zentaris's top competitors are Radius Health, MBX Biosciences, Crinetics